Create

Proprietary in vivo CAR platform that directly programs immune cells within the body using mRNA-LNP delivery, enabling off-the-shelf treatments with demonstrated safety and repeat dosing capability.

First-in-human clinical data confirming mechanism of action with tolerable safety and repeat IV dosing. Multiple programs in clinical trials including Phase 2 studies for frontline HCC and GEJ, with demonstrated complete B cell depletion in non-human primates.